The cytoskeletal components of the myelin fraction are affected by a single intracranial injection of apotransferrin in young rats.
We have previously shown that in rat pups intracranially injected with a single dose of apotransferrin (aTf), there is an early oligodendroglial cell OLGc differentiation. The expression of the mRNAs of myelin basic proteins and of 2',3' cyclic nucleotide 3'-phosphodiesterase and the amount of the corresponding proteins, as well as myelin glycolipids and phospholipids, were significantly increased in these animals at 10 and 17 days of age. Microtubules and myelin basic proteins appear to be closely associated in OLGc and it has been shown that the mRNAs of myelin basic proteins are concentrated in the OLGc processes. The aim of this work was to clarify if the accelerated myelination produced by aTf could be linked to changes in certain cytoskeletal elements present in the myelin fraction such as tubulin, actin, and different microtubule-associated proteins (MAPs). A significant increase in the expression of the mRNA of tubulin and actin was observed in the brain of the aTf-treated animals. Several MAPs, particularly MAP 1B and stable tubule only peptide as well as actin and tubulin, were markedly increased in the Triton X-100 insoluble pellet obtained from the myelin fraction of these animals. The changes that we have previously described in the myelin of aTf intracranially injected rats, could be the consequence of its action on the cytoskeletal network of the OLGc. An enlargement of this structure would result in a more efficient and faster movement of the different components that are normally transported to the myelin by the cytoskeleton of this cell.
Cabrera
O E
OE
Department of Biologicál Chemistry, School of Pharmacy and Biochemistry and Institute of Biological and Physical Chemistry (IQUIFIB), University of Buenos Aires-CONICET, Argentina.
Bongiovanni
G
G
Hallak
M
M
Soto
E F
EF
Pasquini
J M
JM
D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000235:genetics; D000818:Animals; D000831:Animals, Newborn; D001059:Apoproteins / Q000008:administration & dosage / Q000494:pharmacology*; D003598:Cytoskeletal Proteins / Q000235:genetics*; D003599:Cytoskeleton / Q000187:drug effects* / Q000378:metabolism; D005786:Gene Expression Regulation / Q000187:drug effects*; D006017:Glycolipids / Q000378:metabolism; D008845:Microinjections; D004676:Myelin Basic Protein / Q000235:genetics*; D009836:Oligodendroglia / Q000166:cytology / Q000187:drug effects / Q000502:physiology*; D010743:Phospholipids / Q000378:metabolism; D014176:Protein Biosynthesis / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar; D014158:Transcription, Genetic / Q000187:drug effects; D014168:Transferrin / Q000008:administration & dosage / Q000494:pharmacology*
D001059:Apoproteins; D003598:Cytoskeletal Proteins; D006017:Glycolipids; D004676:Myelin Basic Protein; D010743:Phospholipids; D014168:Transferrin; C028284:apotransferrin; D015105:3',5'-Cyclic-AMP Phosphodiesterases